Teva Receives European Marketing Authorization for ZOELY™ Oral Contraceptive

Teva Pharmaceutical Industries Ltd TEVA announced today that its new oral contraceptive, ZOELY™ (NOMAC/E2 –nomegestrol acetate 2.5 mg/17β-estradiol 1.5 mg), has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy. This clears the way to allow the product to be launched in Europe by the end of 2011. Unlike currently available contraceptive pills, ZOELY™ is a combined oral contraceptive tablet containing a unique monophasic combination of 2 steroid hormones; 17-beta estradiol, an estrogen that is structurally identical to the major estrogen produced by the ovaries of healthy non-pregnant women, and nomegestrol acetate, a highly selective progesterone-derived progestin. This innovative combination will be made available in a convenient 24 day active and 4 day placebo dosing regimen.